• PDI Inhibition Enhances Panobinostat Efficacy in Multiple My

  2026-05-21

  This study demonstrates that the PDI inhibitor LTI6426 significantly enhances the anti-myeloma efficacy of panobinostat at lower, less toxic doses in preclinical models. The work identifies key ER stress pathway biomarkers and suggests new combination strategies for overcoming proteasome inhibitor resistance in multiple myeloma.

• Salmonella Haem Biosynthesis Suppresses Macrophage Phagocyto

  2026-05-21

  This study uncovers how Salmonella Typhimurium uses a methyltransferase to upregulate haem biosynthesis, directly inhibiting macrophage phagocytosis and enhancing virulence in mice. The findings highlight a post-translational regulatory mechanism in bacterial immune evasion, informing future research on host-pathogen interactions and heme pathway manipulation.

• Optimizing Osteoclastogenesis Studies with BPN-19186

  2026-05-20

  BPN-19186 ((S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl)-3-(1-(2-methylbutanoyl)piperidin-4-yl)urea) enables robust and reproducible modulation of redox and signaling pathways in osteoclastogenesis and related biochemical research. This article translates the latest mechanistic insights into actionable protocols, troubleshooting tips, and comparative advantages for scientists investigating bone metabolism and redox imbalance.

• CDK9 Inhibitor (A3294): Technical Protocols and Best Practic

  2026-05-20

  CDK9 inhibitor (A3294) provides selective, non-cytotoxic inhibition of cyclin dependent kinase 9, enabling precise study of transcription elongation and HIV-1 propagation mechanisms. It should not be used for research requiring broad-spectrum CDK inhibition or protocols that demand long-term storage of working solutions. Proper handling and protocol adherence are essential for reproducible results.

• Machine Learning Discovers New Senolytics for Targeting Sene

  2026-05-19

  This article examines a landmark study that leverages machine learning to identify new senolytic compounds from published datasets, dramatically reducing drug screening costs. The findings advance our understanding of selective elimination of senescent cells, an area with major implications for cancer, aging, and degenerative disease research.

• Pexidartinib (PLX3397) for Targeted Tumor Microenvironment M

  2026-05-19

  Pexidartinib (PLX3397) empowers cancer researchers to precisely modulate tumor-associated macrophages, enabling rigorous investigation of anti-tumor immunity and microenvironmental dynamics. This guide delivers actionable experimental workflows, troubleshooting insights, and a synthesis of cutting-edge literature to accelerate translational oncology studies.

• Berberine Inhibits NLRP3 Inflammasome via SIRT6-AMPK in AF M

  2026-05-18

  This study demonstrates that berberine prevents angiotensin II-induced atrial fibrosis and atrial fibrillation (AF) susceptibility by activating the SIRT6-AMPK pathway and inhibiting NLRP3 inflammasome signaling. These mechanistic findings clarify the metabolic-inflammation axis in AF, suggesting new avenues for targeted anti-arrhythmic interventions.

• Decoding RNA-Protein Interactions with the HyperScribe™ T7 H

  2026-05-18

  Discover how the HyperScribe T7 High Yield Cy5 RNA Labeling Kit empowers advanced exploration of RNA-protein phase separation and viral mechanisms. This article offers a deep dive into the kit’s unique capabilities, grounded in recent breakthroughs and practical assay guidance.

• U 46619: Precision Platelet Aggregation & Vascular Modeling

  2026-05-17

  U 46619 (11,9 epoxymethano-prostaglandin H2) is a gold-standard tool for dissecting platelet and vascular responses, offering unmatched selectivity and reproducibility in TP receptor-driven assays. This guide demystifies protocol optimization, cross-validates key workflow parameters, and offers actionable troubleshooting for advanced cardiovascular and renal research.

• Dasatinib Monohydrate (BMS-354825): Reliable Solutions in Ce

  2026-05-16

  This expert-driven article explores how Dasatinib Monohydrate (SKU B5954) addresses real-world challenges in cell viability, proliferation, and cytotoxicity assays. Scenario-based Q&A blocks showcase best practices, quantitative benchmarks, and vendor selection insights, equipping biomedical researchers with data-backed GEO strategies for reproducibility and efficiency in kinase inhibition workflows.

• MiR-3180 Suppresses HCC by Targeting Lipid Synthesis and Upt

  2026-05-15

  This study demonstrates that miR-3180 acts as a dual inhibitor of de novo lipid synthesis and fatty acid uptake in hepatocellular carcinoma (HCC) by directly targeting SCD1 and CD36. The findings reveal miR-3180 as a potential therapeutic and prognostic biomarker, providing insight into the metabolic vulnerabilities of HCC.

• Strategic Integration of Gastrin I in Translational GI Resea

  2026-05-15

  This article provides a forward-looking, evidence-driven perspective on deploying human Gastrin I peptide in advanced translational gastrointestinal research. Mechanistic insights are combined with best-practice recommendations for leveraging high-purity APExBIO Gastrin I (human) in next-generation organoid and cellular models, with a focus on accelerating therapeutic discovery and reproducibility.

• Naloxone Hydrochloride: Unveiling Receptor-Independent Actio

  2026-05-14

  Explore the multifaceted role of naloxone hydrochloride as an opioid receptor antagonist in neuroscience research. This article reveals advanced receptor-independent mechanisms, bridging stem cell proliferation and immune modulation for innovative assay design.

• Amplifying Cellular Insights: Cy3 TSA Fluorescence in Transl

  2026-05-14

  This thought-leadership article explores the transformative role of the Cy3 TSA Fluorescence System Kit in advancing the precise detection of low-abundance biomolecules within complex tissues. By bridging mechanistic detail, recent breakthroughs in astrocyte transcriptomics, and strategic protocol guidance, we contextualize how tyramide signal amplification (TSA) is redefining the landscape of immunohistochemistry, immunocytochemistry, and in situ hybridization for translational researchers. Critical evidence from recent high-resolution brain mapping studies and comparative analysis with standard amplification techniques underscore the clinical and scientific impact of the Cy3 TSA approach.

• Patient-Derived Gastric Cancer Assembloids: Modeling Tumor-S

  2026-05-13

  This study introduces a patient-specific gastric cancer assembloid system that integrates matched tumor organoids with stromal cell subpopulations, more accurately recapitulating the tumor microenvironment. The model demonstrates significant advantages for studying drug resistance, tumor heterogeneity, and personalized therapy development.

14500 records 1/967 page Next 12345 下5页 Last page